Opaleye Management’s Odonate Therapeutics, Inc. Common Stock ODT Stock Holding History

Opaleye Management’s Portfolio ODT Stock Details ODT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-250,000	Closed	-$10.6M	–	68
2020 Q2	$10.6M	Sell	250,000 -110,000	-31%	-$3.56M	2.14%	16
2020 Q1	$9.94M	Buy	360,000 +5,000	+1%	+$146K	2.63%	12
2019 Q4	$11.5M	Buy	355,000 +5,000	+1%	+$155K	2.26%	19
2019 Q3	$9.11M	Sell	350,000 -75,000	-18%	-$2.51M	3.29%	8
2019 Q2	$15.6M	Buy	425,000 +100,000	+31%	+$2.4M	4.75%	6
2019 Q1	$7.19M	Buy	325,000 +276,000	+563%	+$4.83M	1.99%	22
2018 Q4	$690K	Buy	+49,000	New	+$763K	0.26%	42

Other funds holding ODT

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Opaleye Management's ODT Position: Q3 2020 in Review

Opaleye Management sold out of Odonate Therapeutics, Inc. Common Stock (ODT) in Q3 2020, closing a stake of 250,000 shares — an estimated $10.6M sold.

Opaleye Management first reported a position in ODT in Q4 2018 and held it in 7 quarters. The position peaked at $15.6M in Q2 2019. 89 funds tracked by Wall St. Rank hold ODT as of Q3 2020.

Opaleye Management reported no remaining Odonate Therapeutics, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
Opaleye Management sold 250,000 Odonate Therapeutics, Inc. Common Stock shares in Q3 2020, an estimated $10.6M.
Opaleye Management first reported a position in Odonate Therapeutics, Inc. Common Stock in Q4 2018 and held it in 7 quarters.
Opaleye Management's Odonate Therapeutics, Inc. Common Stock position peaked at $15.6M in Q2 2019.
89 funds tracked by Wall St. Rank held Odonate Therapeutics, Inc. Common Stock as of Q3 2020.

Based on Opaleye Management's 13F filing for Q3 2020, filed 16 Nov 2020.